FinancialContent

Articles published by Alvotech

< Previous 1 2 3 4 5 6 Next >
News headline image
Alvotech and LOTTE Biologics announce US-based manufacturing agreement to increase global supply
From Alvotech
Via GlobeNewswire
Tickers ALVO
News headline image
FDA approves additional U.S. manufacturing capacity for SIMLANDI®, Alvotech’s biosimilar to Humira®
From Alvotech
Via GlobeNewswire
Tickers ALVO
News headline image
Alvotech Announces FDA Acceptance for Review of Biologics License Application for AVT80, Expanding Proposed Biosimilar Program for Entyvio® to Subcutaneous Presentations
From Alvotech
Via GlobeNewswire
Tickers ALVO
News headline image
Alvotech to present at upcoming investor conferences in September
From Alvotech
Via GlobeNewswire
Tickers ALVO
News headline image
Alvotech Announces Licensing and Commercialization Agreement with Lotus Pharmaceutical for proposed biosimilars to durvalumab and emicizumab in the U.S. and Selected Asian Markets
From Alvotech
Via GlobeNewswire
Tickers ALVO
News headline image
Alvotech Announces Financial Results for the First Half of 2026 and Provides a Business Update
From Alvotech
Via GlobeNewswire
Tickers ALVO
News headline image
Alvotech to Report Financial Results for H1 2026
From Alvotech
Via GlobeNewswire
Tickers ALVO
News headline image
Alvotech announces successful closure of FDA inspection of manufacturing facility
From Alvotech
Via GlobeNewswire
Tickers ALVO
News headline image
Alvotech further strengthens liquidity by securing term loan facility of $75 million
From Alvotech
Via GlobeNewswire
Tickers ALVO
News headline image
Alvotech Announces Closing of Public Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares, Raising an Aggregate of $165 Million with Concurrent Private Placement
From Alvotech
Via GlobeNewswire
Tickers ALVO
News headline image
Alvotech Announces Proposed $125 Million Public Offering and Concurrent Private Placement of Ordinary Shares
From Alvotech
Via GlobeNewswire
Tickers ALVO
News headline image
Alvotech Announces Pricing of $152 Million Public Offering of Ordinary Shares and Concurrent Private Placement
From Alvotech
Via GlobeNewswire
Tickers ALVO
News headline image
Alvotech Announces Proposed $125 Million Public Offering and Concurrent Private Placement of Ordinary Shares
From Alvotech
Via GlobeNewswire
Tickers ALVO
News headline image
Alvotech announces FDA acceptance of Biologics License Application for AVT16, a proposed interchangeable biosimilar to Entyvio®
From Alvotech
Via GlobeNewswire
Tickers ALVO TEVA
News headline image
Alvotech announces resubmission of U.S. Biologics License Applications for AVT05, a proposed biosimilar to Simponi® and Simponi Aria®, and AVT06, a proposed biosimilar to Eylea®
From Alvotech
Via GlobeNewswire
Tickers ALVO TEVA
News headline image
Main Results of 2026 Annual and Extraordinary General Meeting
From Alvotech
Via GlobeNewswire
Tickers ALVO
News headline image
Alvotech to present at upcoming investor conferences in June
From Alvotech
Via GlobeNewswire
Tickers ALVO
News headline image
Alvotech Announces Completion of FDA Surveillance Inspection at Reykjavik Facility
From Alvotech
Via GlobeNewswire
Tickers ALVO
News headline image
Alvotech Q1 2026 Financial Results
From Alvotech
Via GlobeNewswire
Tickers ALVO
News headline image
Alvotech Announces a Change in its Executive Team
From Alvotech
Via GlobeNewswire
Tickers ALVO
News headline image
Alvotech to Report Financial Results for the First Quarter of 2026
From Alvotech
Via GlobeNewswire
Tickers ALVO
News headline image
Alvotech Files Annual Report with the SEC
From Alvotech
Via GlobeNewswire
Tickers ALVO
News headline image
Alvotech Q4 2025 and Full Year 2025 Financial Results
From Alvotech
Via GlobeNewswire
Tickers ALVO
News headline image
Alvotech to Report Fourth Quarter and Full Year 2025 Financial Results
From Alvotech
Via GlobeNewswire
Tickers ALVO
News headline image
Alvotech Announces Positive Top-Line Results from Pivotal Pharmacokinetic Study for Proposed Biosimilar to Entyvio®
From Alvotech
Via GlobeNewswire
Tickers ALVO
News headline image
Alvotech enters supply and commercialization agreements for Canada and Australia & New Zealand covering multiple biosimilar candidates
From Alvotech
Via GlobeNewswire
Tickers ALVO
News headline image
Alvotech Secures Settlement Agreement in Global Markets for its Biosimilar to Eylea® 2mg
From Alvotech
Via GlobeNewswire
Tickers ALVO
News headline image
Alvotech announces planned CEO succession and leadership transition
From Alvotech
Via GlobeNewswire
Tickers ALVO
News headline image
Alvotech Secures Term Loan Facility of USD 100 Million
From Alvotech
Via GlobeNewswire
Tickers ALVO
News headline image
Alvotech announces European launch of first-in-market biosimilar to Simponi® (golimumab) globally by partner Advanz Pharma
From Alvotech
Via GlobeNewswire
Tickers ALVO
< Previous 1 2 3 4 5 6 Next >